Pharma Q2 Preview : Cipla to see steady qtr ; higher profit growth for DRL
Cipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on account of lower Albuterol Sulphate sales. Revenue for the quarter is likely to grow at 13% year-on-year (YoY), according to an average estimate of three (...)
Site référencé: The Economic Times
The Economic Times
Ahead of Market : 10 things that will decide stock market action on Monday
24/08/2025
D-St Week Ahead : Nifty to remain indecisive ; time to avoid fresh aggressive buying
24/08/2025
Sell Axis Bank on Mon. Buy Lupin, 3 more stocks for 10% potential gains tracker
24/08/2025
Fund Manager Talk | Srinivas Rao Ravuri backs beaten-down QSR stocks for a surprise comeback
24/08/2025
Mind Over Money| Gratitude and Gita lessons anchor my leadership journey : Ankit Agarwal, InsuranceDekho
24/08/2025
Hospital sector positioned for double-digit growth ; Apollo Hospitals, Max Healthcare top picks
24/08/2025
